How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Webinar How Do You Know You Have the Right Dose? Using Exposure-Response Evidence to Justify and Defend Dose Decisions Danielle Pillsbury2026 年 10 月 1 日
CODEX Clinical Outcomes Databases Hidradenitis Suppurativa (HS) Fact Sheet CODEX Clinical Outcomes Databases Hidradenitis Suppurativa (HS) Explore Certara's CODEX Hidradenitis Suppurativa database ~43 studies with key efficiency and safety endpoints (HiSCR50,…Danielle Pillsbury2026 年 9 月 25 日
CODEX Clinical Outcomes Databases Chronic Heart Failure (CHF) Fact Sheet CODEX Clinical Outcomes Databases Chronic Heart Failure (CHF) Explore Certara's CODEX Chronic Heart Failure database ~200 studies with key efficiency and safety endpoints…Certara2026 年 9 月 25 日
Modeling effective doses of therapeutic antibodies targeting clustered surface receptors Publication Modeling effective doses of therapeutic antibodies targeting clustered surface receptors Discover how semi-mechanistic PK/receptor-occupancy modeling reveals that lower, subcutaneous doses, not maximum tolerated doses, optimize…Danielle Pillsbury2026 年 9 月 23 日
Model-Informed Strategies for ADC Development White Paper Model-Informed Strategies for ADC Development Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…Danielle Pillsbury2026 年 9 月 22 日
When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing Publication When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing Research shows that particle- and protein-based extracellular vesicle dosing are not interchangeable, supporting a multidimensional…Certara2026 年 9 月 18 日
Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers Publication Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers A semi-mechanistic population PK model characterizes sorfequiline and its active M3 metabolite to support DDI…Certara2026 年 9 月 18 日
External Data Accelerator: Your standards-first team and technology for conformant vendor data Fact Sheet External Data Accelerator: Your standards-first team and technology for conformant vendor data Our tech-enabled team embeds standards and validation from day one, so your data lands clean,…Certara2026 年 9 月 15 日
Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy Poster Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy Pharmacometric modeling of givinostat in pediatric DMD supported a simplified 4-band weight-based dosing regimen without…Certara2026 年 9 月 14 日
Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development Publication Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development A new paper argues context of use, not NAMs-versus-animals, should govern nonclinical strategy in drug…Danielle Pillsbury2026 年 9 月 9 日